Many of us believe that the risk developing bone fractures is more common in men who have stage 4 prostate cancer that has developed distant metastasis than those men with stage 4 prostate cancer that do not have distant metastasis. This increased risk, or actually the increase of fractures has significant clinical consequences, such as [...]
A large meta-analysis of nine studies showed that both oral and IV bisphosphonates were associated with a significantly increased risk of new-onset atrial-fibrillation (AF). The analysis also showed that the risk was greater with the IV drugs. According to the lead author, Dr Abhishek Sharma (Maimonides Medical Center, Brooklyn, NY.) the meta-analysis suggests that bisphosphonates [...]
Higher circulating tumor cell counts are associated with an increased risk of death. Men with metastatic castrate resistant prostate cancer don’t have a good biomarker to predict survival. According to a study published online ahead of print in the Journal of Clinical Oncology. by Amir Goldkorn, MD, and colleagues at the Keck School of Medicine of [...]
Malecare Prostate Cancer Support will present a teleconference titled, "Bone Health and Prostate Cancer.” The conference is scheduled for Tuesday, March 25, 2014 at 6PM ET. The teleconference is available without cost and open to public participation. Simply dial in at 1.800.868.1837 and then enter conference code 156757# (don't forget to press #). 1- Why bone health is [...]
Officials from the National Institute for Health and Care Excellence (Nice) have made a preliminary decision not to recommend covering the drug radium-223 dichloride (Xofigo) for use for men with prostate cancer that has spread to the bone. This latest draft guidance from Nice states that Bayer has not provided information on how Xofigo performs [...]